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Cells exposed to hypoxia experience replication
stress but do not accumulate DNA damage, sug-
gesting sustained DNA replication. Ribonucleotide
reductase (RNR) is the only enzyme capable of
de novo synthesis of deoxyribonucleotide triphos-
phates (dNTPs). However, oxygen is an essential
cofactor for mammalian RNR (RRM1/RRM2 and
RRM1/RRM2B), leading us to question the source
of dNTPs in hypoxia. Here, we show that the RRM1/
RRM2Benzyme is capable of retaining activity in hyp-
oxia and therefore is favored over RRM1/RRM2 in
order to preserve ongoing replication and avoid the
accumulation of DNA damage. We found two distinct
mechanisms bywhich RRM2Bmaintains hypoxic ac-
tivity and identified responsible residues in RRM2B.
The importance of RRM2B in the response to tumor
hypoxia is further illustrated by correlation of its
expression with a hypoxic signature in patient sam-
ples and its roles in tumor growth and radioresist-
ance. Our data provide mechanistic insight into
RNR biology, highlighting RRM2B as a hypoxic-spe-
cific, anti-cancer therapeutic target.
INTRODUCTION
Replication stress is a well-characterized tumor characteristic
and has recently been considered as a potential new hallmark
of cancer (Macheret and Halazonetis, 2015). Replication stress
leads to the activation of the DNA damage response (DDR),
which is associated with the early stages of cancer development
(Bartkova et al., 2005; Gorgoulis et al., 2005). Hypoxia (low oxy-
gen levels) is one of the most physiologically relevant driving
forces of replication stress and is characterized by an increased
number of stalled replication forks and significantly reduced
replication rates. Importantly, hypoxia-induced replication stress206 Molecular Cell 66, 206–220, April 20, 2017 ª 2017 The Authors. P
This is an open access article under the CC BY-NC-ND license (http://occurs in the absence of DNA damage (Olcina et al., 2013).
Regions of hypoxia are observed in preneoplastic lesions in
the majority of tumors. Hypoxia-induced replication stress is
one of the factors proposed to contribute to the selection pres-
sure to lose key components of the DDR, including p53 (Gorgou-
lis et al., 2005; Hammond et al., 2007; Graeber et al., 1996). The
degree of tumor hypoxia is an indicator of poor patient prognosis
due to resistance to most current therapies and increased met-
astatic spread (Begg et al., 2011; Ho¨ckel and Vaupel, 2001).
The importance of ribonucleotide reductase (RNR) lies in its
unique ability to catalyze the rate-limiting step of the reduction
of ribonucleotides (NDPs) to the corresponding deoxyribonucle-
otides (dNDPs), the precursors of DNA (Kolberg et al., 2004;
Stubbe, 1998). Mammalian RNRs consist of two homodimeric
subunits, which associate to form the holoenzyme. The large
RRM1 dimer contains the catalytic site, whereas the smaller
dimer (RRM2or RRM2B) contains an oxygen-requiring di-iron ty-
rosyl-radical site, which is essential for catalysis (Kolberg et al.,
2004; Uhlin and Eklund, 1994; Stubbe et al., 2003). RNR is highly
regulated, as nucleotide imbalances can be detrimental to cell
fate (Aye et al., 2015). Elevated deoxyribonucleotide triphos-
phate (dNTP) pools have been correlated with increased muta-
genesis, while insufficient dNTPs cause replication stress and
promote genomic instability (Bester et al., 2011; Burrell et al.,
2013; Halazonetis et al., 2008; D’Angiolella et al., 2012).
Oxygen is essential for mammalian RNRs to oxidize the di-iron
center found in the smaller subunit (RRM2 or RRM2B) (Huang
et al., 2014). This generates the tyrosyl radical, which via a
long-range pathway, transfers an electron to the catalytic site
of RRM1, enabling the reduction of NDPs to dNDPs (Lundin
et al., 2015; Kolberg et al., 2004; Stubbe et al., 2003). The mech-
anism by which iron is incorporated into the small subunit, and
how oxygen activates the di-iron center for radical initiation, is
still poorly understood and under intense investigation (Huang
et al., 2014; Zhang et al., 2014). The oxygen dependency of
the small RNR subunit has led to the logical assumption that
RNR is inactive in severely hypoxic conditions, something that
has been verified for the RRM1/RRM2 (R1/R2) version of the
RNR enzyme (Brischwein et al., 1997; Chimploy et al., 2000; The-
lander et al., 1983; Reichard, 1993; Probst et al., 1989; Nordlundublished by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Replication Is Compromised, but Not Abrogated, in Oxygen Levels below 0.1%
(A) RPA32 foci in RKO cells exposed to <0.1% O2 and representative images of RPA-negative (normoxia) and positive (<0.1% O2, 3 hr) cells. Scale bar, 10 mm.
(B) Replication rates by DNA fiber analysis in RKO cells exposed to <0.1% O2 and representative images of DNA fibers in normoxia and <0.1% O2 (5 hr). Scale
bar, 10 mm.
(C and D) dNTP levels of purines (C) and pyrimidines (D) in RKO cells exposed to <0.1%O2 or the radical-scavenger hydroxyurea (HU) (2 mM, 6 hr). Data represent
percentage of the control (normoxia).
(E) Immunoblots of RNR subunits in RKO cells exposed to <0.1% O2 for the times indicated.
(F) Representative images of RRM2B immunostaining in normoxia and < 0.1% O2 (18 hr) in RKO cells. Scale bar, 20 mm.
(legend continued on next page)
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and Reichard, 2006). In contrast, we demonstrate that RNR
is able to maintain dNDP formation by switching subunits in hyp-
oxic conditions (<0.1%O2). This switch is critical to preserve suf-
ficient nucleotide levels for ongoing replication and avoid DNA
damage accumulation and apoptosis in hypoxia. Interestingly,
we found that the RRM1/RRM2B (R1/R2B) version of the RNR
enzyme retains activity in hypoxia due to adaptation of RRM2B
to these conditions through two distinct mechanisms. Specif-
ically, we determined that most of the tyrosyl radical in RRM2B
remained stable when exposed to <0.1% O2, a property that
was diminished after disruption of the helix B open conformation
(K37/K151) and the subsequent loss of the crosstalk between
the two monomers. Furthermore, computational simulations
suggest that Y164 plays a role in the fine-tuning of the oxygen-
entering frequency of RRM2B, meaning it is likely to be a better
oxygen-sequestering agent than RRM2. Collectively, our results
reveal a critical role for the RNR (R1/R2B) enzyme in hypoxic
conditions in maintaining sufficient dNTPs for ongoing replica-
tion and therefore preventing DNA damage, genomic instability,
and subsequent loss of viability.
RESULTS
The RRM2B Subunit of RNR Is Induced in Response to
Hypoxia
Cells in hypoxic conditions (<0.1% O2) do not accumulate DNA
damage, although they are characterized by the presence of
replication stress, which leads to the activation of the DDR
(Figures S1A and S1B) (Olcina et al., 2013). As predicted, hyp-
oxia-induced replication stress leads to the accumulation of
single-stranded DNA (ssDNA), which can be detected through
the visualization of replication protein A (RPA) foci in S-phase
cells (Pires et al., 2010). However, the percentage of cells in
hypoxia with RPA foci decreases after prolonged exposure to
these conditions (>6 hr) (Figure 1A). Therefore, our hypothesis
is that although uncoupling of the helicases and polymerases
occurs in hypoxia, replication can proceed. Using DNA fiber
analysis, we confirmed that DNA replication is significantly
slower in hypoxia (25% of normal rate) but is not completely
abrogated (Figure 1B). dNTP incorporation assays were carried
out in RKO cells exposed to hypoxia and demonstrated that,
although the dNTP pools were disrupted (with the purines
[dGTP, dATP] being more affected than the pyrimidines [dCTP,
dTTP]), there was nucleotide availability in hypoxic conditions
(Figures 1C and 1D). The differences observed between purine
and pyrimidine pools are not fully understood. It has been
suggested that pyrimidine levels persist due to compensatory
activities of the pyrimidine salvage pathways or as a result of
the deoxyuridine present in culture medium, which cells could
uptake and phosphorylate, therefore contributing to pyrimidine
levels, particularly dTTP (Eriksson et al., 1987; Bianchi et al.,
1986). Interestingly, the pyrimidine salvage pathway has been(G) mRNA levels of RNR subunits in RKO cells in <0.1% O2 normalized to 18S.
(H) Expression of RRM2B (log10 conversion) in a colorectal adenocarcinoma TCG
For all panels (except H), n = 3 (biological replicates); for (A)–(D) and (G), data show
significant change. See also Figure S1.
208 Molecular Cell 66, 206–220, April 20, 2017reported to be more efficient than the purine pathway, suggest-
ing an explanation for why purine levels are more sensitive to
hydroxyurea (HU) and potentially hypoxia (Reichard, 1988). Our
data demonstrate sufficient nucleotide availability in hypoxia
to allow replication to proceed, albeit at a compromised rate;
thus raising the possibility that RNR is able to retain some activity
in hypoxia.
Expression analysis of the RNR complex showed that the
RRM2B protein is significantly induced (2- to 3.5-fold, depend-
ing on cell line) in response to hypoxia in cell lines, including
colorectal, osteosarcoma, glioblastoma, and esophageal cancer
cells, whereas the RRM2 small subunit decreased over time and
the RRM1 remained unchanged or showed a slight decrease
(Figures 1E, 1F, and S1C–S1F). As RKO cells showed the highest
level of RRM2B expression, we chose it as a model line for the
majority of our experiments (Figure S1G). Similar results were
obtained when mRNA levels were assayed. RRM2B increased
4.6-fold after 24 hr in hypoxic conditions, whereas RRM2 and
RRM1 mRNA levels decreased 12.3- and 2.5-fold, respectively
(Figures 1G and S1H). Importantly, in silico TGCA (The Cancer
Genome Atlas) analysis of colorectal adenocarcinoma patient
cohorts demonstrated that RRM2B expression correlates signif-
icantly with the expression of a verified hypoxia signature (Fig-
ure 1H), suggesting that the oxygen-dependent overexpression
of RRM2B also occurs in vivo (Li et al., 2014). In contrast, RRM1
and RRM2 expression did not correlate with the same hypoxic
signature (Figures S1I and S1J). Interestingly, overexpression
and genetic alterations in RRM2B correlated with worse overall
and disease-free survival in colorectal cancer patients (Figures
S1K–S1N).
The transcription factor HIF-1 (hypoxia-inducible factor 1) is
known to mediate significant gene expression changes in
response to hypoxia and has roles in DNA replication, DNA repair,
and respiration (Hubbi et al., 2013; Fukuda et al., 2007; Crosby
et al., 2009). Therefore, we investigated if the induction of
RRM2B in hypoxia was dependent on HIF-1a by utilizing
RKOHIF-1a +/+ andRKOHIF-1a / cells exposed to hypoxia (Figures
2A, S2A, and S2B). Interestingly, both the mRNA and the protein
levels of RRM2B were induced in hypoxia irrespective of HIF-1a
status, in contrast to the well-documented HIF-1a target
GLUT1. Next, using RKOHIF-1a +/+ cells exposed to either 2%
or <0.1% O2, we investigated the oxygen dependency of the in-
duction of RRM2B protein. RRM2B was induced in response to
the lower level of hypoxia (<0.1% O2), where a robust p53 induc-
tionwas also observed but did not increase in response to 2%O2
despite HIF-1a stabilization (Figure 2B). This finding is in agree-
ment with our previous studies demonstrating that the lower level
of hypoxia (<0.1% O2) induces replication stress and that this is
the signal that initiates theDDR (includingp53 stabilization) (Ham-
mond et al., 2002; Olcina et al., 2013).
RRM2B was first characterized as a p53-regulated RNR
subunit (p53R2) (Tanaka et al., 2000). Here, further analysis ofA dataset is shown against the hypoxia-inducible signature (log10 conversion).
means ± SEM and one-way ANOVA analysis was applied; (ns) indicates a non-
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Figure 2. RRM2B Is Induced in Hypoxia
(A) mRNA levels of RRM2B and GLUT1 in RKOHIF-1a+/+ and RKOHIF-1a/ cells in <0.1% O2 assayed by qPCR and normalized to 18S.
(B) Immunoblots of RKO cells exposed to 2% and <0.1% O2 for the times indicated. p53 and RRM2B protein induction are observed only in <0.1%O2.
(C and D) Immunoblots (C) and RRM2B mRNA levels (D) of HCT116p53+/+ and HCT116p53/ exposed to <0.1% O2 for the times indicated.
(E) qPCR for p53 ChIP in RKO cells treated with Adriamycin (2 mM, 6 hr) or exposed to either normoxia or <0.1% O2 (6 hr).
(F) Immunoblots of RKO cells treated as in (E).
(G) Expression of RRM2B (log10 conversion) in the colorectal adenocarcinoma TCGA datasets is shown against hypoxia dependent p53-inducible group of
genes (log10 conversion).
(H) Immunoblots of RNR subunits in H1299p53/ (non-small cell lung carcinoma) cells exposed to <0.1% O2 for the times indicated.
For all panels (except G), n = 3 (biological replicates); data in (A) and (D) represent mean ± SEM; and (E) shows representative mean of technical triplicates ±
RQmax/RQmin. HIF-1a status and p53 status was examined by two-way ANOVA analysis; two-tailed Student’s t test was applied in (E); (ns) indicates a non-
significant change. See also Figure S2.the molecular pathways mediating RRM2B induction in hyp-
oxia demonstrated that the hypoxic overexpression of RRM2B
occurs in a p53-dependent manner (Figures 2C, 2D, and S2C–
S2H). To rule out the possibility of an indirect mechanism of
induction of RRM2B by p53, chromatin immunoprecipitation
(ChIP) assays were carried out and demonstrated that p53 binds
directly to the p53-response element at the RRM2B locus lead-ing to transcriptional overexpression (Figures 2E, 2F, and S2I–
S2K). Interestingly, although p53 expression was increased in
response to the DNA damaging agent Adriamycin, this did not
correlate with increased p53 binding to the p53-response
element in RRM2B (Figures 2E and 2F). Most importantly, anal-
ysis of the TCGA colorectal adenocarcinoma patient cohorts
showed that RRM2B expression significantly correlated with aMolecular Cell 66, 206–220, April 20, 2017 209
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Figure 3. Effects of RRM2B Depletion in Hypoxia
(A) Immunoprecipitation of RRM1 followed by immunoblotting for RRM2B and RRM2 in normoxia and <0.1% O2 (18 hr).
(B) dNTP levels in RKO cells treated with non-specific (siCTL) or siRRM2B and exposed to <0.1% O2 (16 hr).
(C) FACS analysis of U2OS cells treated with siCTL or siRRM2B and exposed to normoxia or <0.1% O2 (3 hr). Cells were pulsed with bromodeoxyuridine (BrdU)
(20 mM) 30 min before collection.
(D) RPA32 foci in RKORRM2B+/+ and RKORRM2B/ cells after exposure to <0.1% O2.
(E) 53BP1 foci in RKORRM2B+/+ and RKORRM2B/ cells exposed to normoxia or <0.1% O2 (6 hr).
(legend continued on next page)
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recently identified group of hypoxia-inducible p53-dependent
genes (Leszczynska et al., 2015), suggesting that hypoxia- and
p53-dependent expression of RRM2B occurs in human cancers
(Figure 2G). Interestingly, in p53 null cell lines (H1299p53/,
HCT116p53/) a mild (1.3- to 1.7-fold) increase in RRM2B pro-
tein levels was also observed in hypoxia (Figures 2C and 2H).
These findings suggest that additional post-translational p53-in-
dependent mechanisms exist for RRM2B stabilization and there-
fore the importance of RRM2B in hypoxic conditions.
RRM2B Replaces RRM2 in Hypoxia
In order to investigate the biological significance of hypoxia-
induced RRM2B, we first verified that it forms a complex with
the RRM1 subunit to reconstitute the R1/R2B holoenzyme
in <0.1% O2. Immunoprecipitation assays demonstrated that
increased levels (5.3-fold) of RRM2B protein were bound to the
RRM1 subunit in hypoxia whereas the levels of RRM2 bound
to RRM1 decreased by 1.8-fold (Figures 3A, S3A, and S3B).
Next, we asked if the hypoxia-formed R1/R2B enzyme was
functional. Small interfering RNA (siRNA)-mediated loss of
RRM2B led to significantly lower intracellular dNTP levels in
hypoxia (50%–55% less pyrimidines and 25%–30% less
purines compared to the control [siCTL]) (Figures 3B and S3C).
In contrast, the loss of RRM2B did not significantly affect the
dNTP pools in normoxic conditions (Figure S3D). In addition,
fluorescence-activated cell sorting (FACS) analysis demon-
strated that S-phase U2OS cells lacking RRM2B incorporate
37.5% less BrdU than the control-treated cells in hypoxia (Fig-
ures 3C and S3E). These findings demonstrate that depletion
of RRM2B in hypoxia leads to further disruption of the dNTP
pools and indicate that ongoing replication is disrupted.
To further investigate the hypoxic role of RRM2B, we used
CRISPR/Cas9 technology to construct a RRM2B knockout cell
line (RKORRM2B/) (Figures S3F–S3I). RRM2B-depleted RKO
cells (both knockout and siRNA treated) showed a persistent
formation of RPA foci during long (24 hr) exposures to hypoxia,
suggesting an accumulation of ssDNA and failure to complete
DNA replication (Figures 3D and S4A–S4C). Furthermore, cells
with reduced levels of RRM2B formed 53BP1 foci indicating
the presence of double-strand breaks (DSBs) specifically in hyp-
oxia (Figures 3E, 3F, and S4D–S4F). No evidence of elevated
DNA damage was observed in control cells or in cells lacking
RRM2B in normoxia; this was attributed to the RRM2-dependent
supply of dNTPs when oxygen is abundant. The increased DSBs
observed in hypoxic cells with depleted RRM2B correlated with
(1) a significant loss of viability measured by colony survival
assay (77% fewer cells survived after 24 hr of hypoxia when(F) Representative images of 53BP1 foci in RRM2B-negative RKO cells treated w
(G) Colony survival assay in RKO cells treated with siCTL or siRRM2B and expo
(H) Apoptosis detected morphologically in RKO cells treated with siCTL or siRRM
(I) RKORRM2B+/+ andRKORRM2B/ cells were grown as xenografts inmice (n = 4m
reached 100 mm3.
(J) Representative images of co-localization of cleaved caspase-3 (apoptosis) w
bars, 50 mm.
(K and L) Tumors were removed on day 28 post-implantation (from Figure S5H), a
and hypoxic areas (PIMO positive) (L). Images from three different tumors (n = 3
For all panels, n = 3 (biological replicates) unless otherwise stated. Data showmea
way ANOVA analysis was applied, and (I), where two-way ANOVA analysis wasRRM2B was silenced in comparison to siCTL) (Figure 3G) and
(2) the induction of apoptosis as determined both morphologi-
cally and by induction of PARP cleavage (Figures 3H and S4G).
Notably, xenograft tumors of RKORRM2B+/+ and RKORRM2B/
cells showed delayed tumor growth and increased radiosensi-
tivitywhenRRM2Bwas lacking (Figures 3I andS4H). Additionally,
a significant increase in apoptosis specifically in the hypoxic re-
gions of the RRM2B/ tumors was observed (Figures 3J–3L)
as determined by the presence of cleaved caspase-3 (apoptosis)
in the pimonidazole (PIMO)-positive (hypoxic) regions. Increased
apoptosis in the hypoxic fraction of the tumors offers a likely
explanation for the increased radiosensitivityobserved (Figure3I).
The data presented so far suggest that the basal levels of
dNTPs provided by R1/R2B (as opposed to R1/R2) are sufficient
for ongoing replication in hypoxic cells, preventing the collapse
of replication forks that would ultimately lead to DSBs and loss
of viability. These data indicate that RRM2B contributes to the
increased resistance of the most aggressive fraction of tumors;
therefore, we investigated the hypoxic adaptation of RRM2B
by determining the enzymatic properties of both forms of RNR
enzyme (R1/R2 and R1/R2B) in normoxia and hypoxia.
RRM2B Retains Enzymatic Activity in Hypoxia
RRM1, RRM2, and RRM2B recombinant proteins were over-
expressed and purified from E. coli (Figures S5A and S5B),
without additional iron or reductants, to prevent the variability
associated with in vitro assembly of the active cluster of the
tyrosyl radical (Cotruvo and Stubbe, 2011). We quantified the
iron bound to RRM2 and RRM2B using inductively coupled
plasma (ICP) mass spectrometry and found comparable iron
incorporation between the two recombinant proteins (Fig-
ure S5C). The level of iron incorporation was 10% of the level
that has been reported in a fully loaded RRM2, which would in
turn predict lower enzymatic activity (Aye et al., 2012b; Ochiai
et al., 1990).
The abilities of the two forms of the RNR enzyme (R1/R2B
and R1/R2) to reduce cytidine diphosphate (CDP) (substrate) to
deoxycytidine diphosphate (dCDP) (product) were assayed in
normoxic and hypoxic conditions (<0.1% O2). As hypothesized,
the R1/R2B was able to sustain activity in both <0.1% O2 and
normoxia with no statistically significant difference in the total
amount of dCDP formed under either condition after 30 min (Fig-
ure 4A). In fact, the R1/R2B enzyme continued convertingCDP to
dCDP for over 2 hr in hypoxia (Figures 4B and S5D). In contrast,
the R1/R2 enzyme did not sustain activity in hypoxia (Figure 4C)
and stopped producing dCDPs after 15min in <0.1%O2 (Figures
4D and S5D). Importantly, we verified that the R1/R2 enzyme didith siRRM2B and exposed to normoxia or <0.1% O2 (6 hr). Scale bar, 20 mm.
sed to normoxia or <0.1% O2 (24 hr).
2B and exposed to normoxia or <0.1% O2 (19 hr).
ice per each group).Where indicated, irradiation (10Gy) was givenwhen tumors
ith PIMO (hypoxic areas) in RKORRM2B+/+ or RKORRM2B/ xenografts. Scale
nd the level of apoptosis was quantified in normoxic areas (PIMO negative) (K)
) per group were counted.
n ± SEM and two-tailed Student’s t test was applied, except in (D), where one-
applied. (ns) indicates a non-significant change. See also Figures S3 and S4.
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Table 1. O2 Residence Times around the Fe Metallocenter for
RRM2B and RRM2 Proteins
System
Time
(ns)
O2, Fe
Residence
Time (ns)
O2 Entering
Events
Entering
Frequency
(%)
RRM2B
monomer 1
300 O2, 79 25 25 68
O2, 80 19
O2, 120 36
O2, 125 25
RRM2B
monomer 2
300 O2, 93 49 8 22
O2, 107 9
O2, 126 38
O2, 175 103
RRM2
monomer 1
300 O2, 19 3 5 14
O2, 22 11
O2, 37 2
O2, 142 5
RRM2
monomer 2
300 O2, 8 19 0 0
O2, 65 20
O2, 88 14
O2, 122 9not stop dCDP formation in hypoxia due to lack of available CDP
(Figure S5E). Collectively, these data suggest that the compro-
mised R1/R2 activity observed at <0.1% O2 was a result of
limited oxygen availability. It is important here to state that
the oxygen does not affect the stability of the tyrosyl radical,
and it is only required for tyrosyl radical formation (Stubbe,
2003). Once assembled, the tyrosyl radical can catalyze multi-
ple turnovers until regeneration is necessary, with mammalian
R1/R2 being stable for 15–25 min in vitro (Cotruvo and Stubbe,
2011). The key difference observed between R1/R2B and
R1/R2 in hypoxia offers a mechanistic explanation for why
the R1/R2B form of RNR is preferred in hypoxic conditions. It
should be noted that, as previously described, the overall activ-
ity of the RRM2B-containing RNR enzyme is significantly lower
than that of the RRM2-containing RNR (Shao et al., 2004) (Fig-
ures 4B and 4D). Therefore, although our data suggest that
R1/R2B is the preferred RNR enzyme in hypoxia, the levels of
available nucleotides are still reduced compared to normoxia,
thus explaining the continued replication stress in these condi-
tions (Figure 1A).Figure 4. RRM2B Retains Activity in Hypoxia
(A) Product formation (percentage of the maximum, where maximum is the dCDP
(B) dCDP (mM) in <0.1%O2 for R1/R2B for the times indicated. Activity of R1/R2B
Gray columns indicate the amount of dCDP formed up to 15 min in <0.1% O2, an
(C) Product formation (percentage of the maximum, where maximum is the dCD
(D) dCDP (mM) in <0.1%O2 for R1/R2 for the times indicated. Activity of R1/R2 enz
columns indicate the amount of dCDP formed up to 15 min in <0.1% O2, and re
(E and F) Characterization of the oxygen tunnels (T1–T3) of RRM2B (E) and RRM
(G and H) EPR spectra of the tyrosyl radical of RRM2B (G) and RRM2 (H) in norm
(I) Quantification of (G) and (H). Data present electron spins per b subunit.
For all panels, n = 3 (biological replicates); for (A) and (C), data represent mean ±
SEM and two-tailed Student’s t test was applied; (ns) indicates non significant cAdaption of RRM2B to Hypoxic Environments
Given the differences in normoxic and hypoxic activity between
RRM2B and RRM2, we compared the potential oxygen accessi-
bility for the proteins using a modeling approach. Using the only
available published structures of RRM2B (PDB: 3HF1) and
RRM2 (PDB: 3VPN) (Smith et al., 2009), we investigated the
theoretical differences and/or similarities in the dynamics of
oxygen diffusion between the two proteins using classical mo-
lecular dynamics (MD) simulations. The intention of this study
was to understand how molecular oxygen accesses the core
of the protein and to probe whether any differences could be
related to the activities of RRM2/RRM2B in normoxia versus
hypoxia. Our analysis revealed three principal oxygen cavity
tunnels (T1–T3) in both proteins, which could be employed as
access points (Figures 4E, 4F, and S5F). Analysis of T1–T3 sug-
gested that RRM2B could act as a better oxygen-sequestering
agent than RRM2. Specifically, we found that the predicted
oxygen-entering frequencies are greater for RRM2B (68% at
monomer 1 and 22% at monomer 2) than for RRM2 (14% at
monomer 1 and 0% at monomer 2) (Table 1), which indicate dif-
ferential oxygen-turnover susceptibilities between RRM2B and
RRM2. In addition, free-energy calculations of oxygen entry
through tunnels T1, T2, and T3 (Figure S5G) suggest that the
origin of the selectivity between RRM2B and RRM2 for oxygen
turnover resided primarily in tunnels T2 and T3, meaning that
the energy barriers for oxygen to cross T2 and T3 are higher
for RRM2 than for RRM2B.
We then performed electron paramagnetic resonance (EPR)
spectroscopy to monitor the stability of the tyrosyl radical of
the two proteins in hypoxic conditions (Figures 4G and 4H).
Strikingly, we observed that 66% ± 3.35% of the tyrosyl
radical in RRM2B remained stable for 1 hr at 37C in <0.1%
O2, while in the same conditions, only 43% ± 4% remained
stable in RRM2 (Figure 4I). Collectively, our results provide
compelling evidence that RRM2B is able to retain activity in
hypoxia while the activity of RRM2 is compromised and there-
fore highlight a specific role for RRM2B in the hypoxic stress
response.
Hypoxic Activity of RRM2B Is Dependent on K37/K151
and Y164
Despite the fact that RRM2 and RRM2B share 83% sequence
homology, there are distinct functional and structural differences
(Shao et al., 2004; Smith et al., 2009; Zhou et al., 2010; Xue et al.,
2006; Wang et al., 2009b). The switch of C202 in RRM2 to Y164levels at 30 min in normoxia) for R1/R2B enzyme in normoxia and <0.1% O2.
enzyme at 37C at 5 min in <0.1%O2 was 19.57 nmol/min/mg RRM2B protein.
d red columns indicate the amount of dCDP formed after 15 min in <0.1% O2.
P levels at 30 min in normoxia) for R1/R2 enzyme in normoxia and <0.1% O2.
yme at 37C at 5min in <0.1%O2 was 97.74 nmol/min/mg RRM2 protein. Gray
d columns indicate the amount of dCDP formed after 15 min in <0.1% O2.
2 (F).
oxia and <0.1% O2, respectively.
SEM and two-way ANOVA was applied; for (B) and (D), data represent mean ±
hange. See also Figure S5.
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Table 2. O2 Residence Times around the Fe Metallocenter for
RRM2B Mutants
System
Time
(ns)
O2, Fe
Residence
Time (ns)
O2 Entering
Events
Entering
Frequency
(%)
Y164C
monomer 1
300 O2, 57 30 8 14
O2, 79 6
O2, 124 9
O2, 139 60
Y164C
monomer 2
300 O2, 1 9 17 29
O2, 105 14
O2, 167 7
O2, 191 16
K37E/K151E
monomer 1
300 O2, 37 30 37 64
O2, 40 32
O2, 47 47
O2, 27 27
K37E/K151E
monomer 2
300 O2, 9 9 6 16
O2, 188 4
O2, 190 5
O2, 198 3in RRM2B results in an open phenylalanine channel specifically
in RRM2B (Smith et al., 2009), which is connected with oxygen
T3 (Figures S5F and S5H). It has been proposed that F183 in
RRM2B versus Y221 in RRM2 contributes to the differences in
the enzymatic activity between the two proteins (Zhou et al.,
2010). In addition, RRM2B has unique antioxidant capabilities,
which are partially due to the Y241 and Y331 residues (H279
and Y369 in RRM2) (Xue et al., 2006). Finally, RRM2B through
K37 and K151 (E76 and E190 in RRM2) exhibits greater crosstalk
between its secondary structures, which stabilizes helix B in an
open conformation (Smith et al., 2009). Based on these key dif-
ferences between RRM2 and RRM2B (Figure S6A) and in order
to determine the regions of RRM2B responsible for hypoxic
adaptation, we constructed, overexpressed, and purified seven
recombinant RRM2B mutants: Y164C, Y164F, F183Y, K37E/
K151E, Y241H, Y331F, and Q127K (Figure S6B). The Q127K
mutant was generated as a negative control, as it diminishesFigure 5. Critical Roles of K37/K151 and Y164 in RRM2B
(A and B) Product formation (percentage of the maximum, where maximum is t
normoxia and <0.1% O2.
(C) EPR spectra of the tyrosyl radical of Y164C, K37E/K151E, and Q127K (as a n
(D) Quantification of (C). Data present electron spins per b subunit.
(E) The RRM2B phenylalanine network around Y164 and phenylalanine conforma
distance. Color code: WT (black), Y164C (red).
(F and G) dATP (F) and dTTP (G) levels in RKORRM2B/ cells transfected with CT
(H) Immunoblot for PARP cleavage in RKORRM2B/ cells treated as in (F) and (G
(I) Apoptosis detected morphologically in RKORRM2B/ cells treated as in (H).
(J) Schematic representation of our proposed model. Hypoxia leads to severely
induced through the DDR pathway to maintain ongoing replication. However, insu
The importance of RRM2B activity is that while it does not resolve replication stre
DNA damage and loss of genome stability.
For (A), n = 3; for (B), n = 4 (biological replicates) and two-way ANOVA was applied
represent means ± SEM and two-tailed Student’s t test was applied. See also Fenzymatic activity due to disruption of the stability of the radical
cluster (Zhou et al., 2010).
The seven purified mutants showed the same secondary
structure, determined by circular dichroism, as the wild-type
RRM2B recombinant protein (Figure S6C). The levels of iron
incorporation were also similar for the mutant with the exception
of Q127K, as expected (Figure S6D). Reduction of CDP to dCDP
was assayed in hypoxia for these mutants. Sustained reduction
of CDP to dCDP was observed for 2 hr for most mutants, except
Y164C and K37E/K151E, which both appeared to stop reducing
substrate after 30 min in hypoxia, reminiscent of R1/R2 (Fig-
ures S6E–S6K). For these two mutants, we then compared
dCDP formation in normoxia and hypoxia and found that the abil-
ity to reduce CDP to dCDP in hypoxia was compromised in both
the K37E/K151E and Y164Cmutants (Figures 5A and 5B). These
results indicate that these specific residues are critical to the role
of RRM2B in hypoxia and that without them, RRM2B activity is
not sustained, similar to RRM2.
To further probe the role of K37/K151 and Y164, we performed
additional EPR analyses and MD simulations. Using EPR spec-
troscopy, we observed that while most of the RRM2B mutants
behaved as the WT-RRM2B, which retains 60%–79% of its
tyrosyl radical in hypoxia (Figure S7A), the K37E/K151E mutant
retained only 28% of its tyrosyl radical in these conditions (Fig-
ures 5C and 5D). Since K37/K151 residues affect helix B of
RRM2B monomer 2, the bending angle of the helices was esti-
mated and showed that helix B in RRM2B is in an open confor-
mation (20–25 bending angle), whereas in RRM2, it is closed
(8–10) (Figure S7B). Interestingly, MD simulations for the
K37E/K151E variant showed a closure of helix B after 300 ns
from 20 to 8 bending angle, therefore resembling the closed
conformation of RRM2 (Figures S7B and S7C). Although these
are theoretical studies that provide only indications of the protein
conformation, the distortion of helix B in monomer 2 of the K37E/
K151E mutant could suggest loss of the essential crosstalk
between the two monomers, which may explain the loss of
tyrosyl radical stability in hypoxia as demonstrated by our EPR
analysis.
Additionally, MD simulations showed a 4.8-fold lower oxy-
gen entering frequency for the Y164C mutant in comparison to
WT-RRM2B, while we did not observe any changes in the oxy-
gen entering frequency for the K37E/K151E mutant (Table 2).he dCDP levels at 30 min in normoxia) for K37E/K151E (A) and Y164C (B) in
egative control) in normoxia and <0.1% O2.
tion in Y164C mutation. Distance plot reveals the effect of Y164C in F95-F197
L, WT, Y164C, or K37E/K151E and exposed to <0.1% O2 (16 hr).
) plus Q127K and exposed to <0.1% O2 (19 hr).
compromised activity of RRM2, leading to replication stress. RRM2B is then
fficient dNTPs are generated by R1/R2B, and replication stress is unresolved.
ss, it does maintain replication fork integrity and prevents the accumulation of
; for (C), n = 2 (biological replicates); for (F)–(I), n = 3 (biological replicates); data
igures S6 and S7.
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This could be explained by disruption of the Y164-F197 and
Y164-F198 contacts in monomer 1 of RRM2B, which could
cause side-chain rearrangement of F95 in the Y164C mutant.
This rearrangement may result in F95 moving closer to F197,
leading to closure of the RRM2B specific phenylalanine channel
(Figures 5E and S5H), therefore explaining the lower oxygen-
entering frequency in Y164C mutant.
Finally, in order to demonstrate that our findings are relevant
in cells experiencing hypoxia and that the hypoxic adapta-
tion of RRM2B depends on the identified residues (Y164
and K37/K151), we performed rescue experiments by trans-
fecting our RKORRM2B/ cells with the following constructs:
pRRM2BWT, pRRM2BY164C, pRRM2BK37E/K151E, and pcDNA3.1
(CTL). As expected, when WT-RRM2B was reintroduced, a
significant increase in the intracellular nucleotide levels was
observed in hypoxia, whereas reintroduction of Y164C and
K37E/K151E showed significantly lower dNTP levels compared
to WT-RRM2B (Figures 5F, 5G, S7D, and S7E). Additionally, by
monitoring apoptosis, we observed that WT-RRM2B rescued
the null phenotype from apoptosis, whereas loss of the key res-
idues (Y164 and K37/K151) abrogated this rescue (Figures 5H
and 5I), therefore validating our in vitro experiments and theoret-
ical studies. Overall, we demonstrate the critical importance of
the hypoxic induction of RRM2B to mitigate replication stress
and determine the molecular adaptations of RRM2B to hypoxia
to support this function (Figure 5J).
DISCUSSION
We identified that in response to the physiological stress of hyp-
oxia, RNR responds by isoform switching favoring RRM2B over
RRM2. In hypoxia the activity of RRM2 is severely compromised
due to the lack of available oxygen, leading to replication stress.
RRM2B is able to retain its activity in hypoxia and is therefore
induced to compensate and facilitate ongoing replication. This
property of RRM1/RRM2B, although not sufficient to resolve
replication stress, does preserve replication fork integrity and
prevent the accumulation of DNA damage in hypoxia. We
verified that depletion of RRM2B results in lower dNTP levels
in hypoxic cells and that this has detrimental consequences for
cell fate (failure to complete DNA replication, DNA damage,
and loss of viability). Importantly, loss of RRM2B in a xenograft
model showed delayed tumor growth, increased radiosensitivity,
and increased apoptosis specifically in hypoxic areas, further
highlighting the biological importance of the hypoxic induction
of RRM2B.
Our data suggest that RRM2B is capable of retaining activity
in hypoxia through two mechanisms: (1) increased oxygen-
entering frequency and (2) enhanced stability of the tyrosyl
radical. Our MD analyses suggested that Y164 could increase
the oxygen-entering frequency through oxygen tunnel T3 in
monomer 1 by keeping F95 an optimum distance from F197.
We also found that through the K37/K151 residues, the
RRM2B protein retains 66%–70% of its tyrosyl radical in hypox-
ia. Interestingly, monomer 2 of RRM2B showed a higher oxy-
gen-entering frequency than RRM2 (22% and 0%, respectively),
suggesting that the two monomers of the small RNR subunits
could react differently in the overall production of the tyrosyl216 Molecular Cell 66, 206–220, April 20, 2017radical. It is possible that monomer 2 contributes more to the ty-
rosyl radical in RRM2B than in RRM2, possibly due to its helix B
open conformation, and that this could be more relevant in
hypoxic conditions. In support of this hypothesis, EPR spectra
of the double mutant, K37E/K151E, showed a marked reduction
in the tyrosyl radical content in hypoxia, but not in normoxia. We
propose that the tyrosyl radical of monomer 2 is better protected
in RRM2B, therefore contributing to the prolonged activity of the
enzyme in hypoxic environments. Our proposed model, where
both monomers contribute to tyrosyl radical formation, is in
agreement with the established finding that the tyrosyl radical
is equally distributed between each small subunit, suggesting
the possibility of generation of two tyrosyl radicals per dimer
(Cotruvo and Stubbe, 2011). It is important to note that our MD
simulations were carried out with the only currently available
crystal structure of human RRM2B protein (PDB: 3HF1), which
has limitations in its active site configuration and specifically in
the iron center. However, we considered it unlikely that as a
result of this, there would be large conformational changes in
the global structure of the protein compared to its native state,
at least to a degree that would influence ourMD analysis. Indeed,
this is supported by the results of our recombinant mutant
analysis and, most importantly, our rescue experiments using
our RRM2B knockout cell line. Collectively, this work highlights
the importance of Y164, K37, and K151 for RRM2B activity in
hypoxia. It is important to note that the recombinant proteins
used in our biochemical assays were assembled without addi-
tional iron. The biochemistry of RNR, especially the reconstitu-
tion of the tyrosyl radical, is extremely complex and not fully
understood. Additional studies that also consider the relevant
factors for accurate assembly are required and will likely further
illuminate the role of RRM2B in both normoxia and hypoxia.
To date, mammalian RRM2B has been primarily associated
with DNA repair and mitochondrial DNA synthesis (Wang et al.,
2009b; Pontarin et al., 2012). However, it is probable that
RRM2B has been evolutionarily maintained in order to be used
as the hypoxic-specific RNR small subunit, especially as vari-
ants of RRM2B protein have been found to be responsible for
continued cell division in anoxia tolerant vertebrates (Sandvik
et al., 2012). Here, we propose that one of the principal functions
of RRM2B is to act as the hypoxic-specific RNR subunit in order
to be able to react promptly when this physiologically relevant
stress occurs. It is tempting to speculate that through antioxidant
and catalase-like properties (Xue et al., 2006), RRM2B might
even play a role in increasing immediate oxygen availability.
Interestingly, a number of previous reports have demonstrated
that RRM2B is frequently affected by copy-number changes,
typically showing gains, in a broad range of cancers (Chae
et al., 2016; Jørgensen et al., 2013). This has led to the sugges-
tion that RRM2B is a tumor promoter (Aye et al., 2015). Our
study demonstrates that increased RRM2B expression in hyp-
oxia maintains replication and prevents DNA damage, therefore
providing a plausible explanation for why RRM2B is so often
amplified in cancers.
Our data suggest that targeting R1/R2B enzyme specifically in
hypoxic tumor cells might be an effective therapeutic strategy.
RNR is a well-established therapeutic target, and a number of
RNR inhibitors (such as gemcitabine, clofarabine, hydroxyurea,
and triapine) are being used clinically (Manegold et al., 2000;
Aye and Stubbe, 2011; Aye et al., 2012a; Levin, 1992; Sterkers
et al., 1998; Hehlmann et al., 1993; Nutting et al., 2009). Inter-
estingly, delivery of siRNA against RRM2 by phosphorothionate
oligodeoxynucleotides (GTI-2040) (Lee et al., 2003) is in clinical
trials for various solid tumors (Juhasz et al., 2006; Leighl et al.,
2009; Oh and Park, 2009). It is tempting to speculate that if this
approach was modified to target RRM2B and was employed
alongside patient stratification to identify those with significant
tumor hypoxia, it may be an effective way to target the most
aggressive and treatment-resistant fraction of tumors.
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Antibodies
Goat polyclonal anti-RRM1 (T-16) Santa Cruz Cat# sc-11733
Goat polyclonal anti-RRM2 (N-18) Santa Cruz Cat# sc-10844
Goat polyclonal anti-p53R2 (N-16) (RRM2B) Santa Cruz Cat# sc-10840
Mouse monoclonal anti-Chk1 (G-4) Santa Cruz Cat# sc-8408
Mouse monoclonal anti-p53 (DO-1) Santa Cruz Cat# sc-126
Rabbit polyclonal anti-p53 (FL-393) Santa Cruz Cat# sc-6243
Mouse monoclonal anti-b-Actin Antibody (AC-15) Santa Cruz Cat# sc-69879
Mouse anti-Human HIF-1a Clone 54 BD Transduction Laboratories Cat# 610958
Mouse anti-BrdU Clone B44 BD Transduction Laboratories Cat# 347580
Rat monoclonal anti BrdU Clone BU1/75 (ICR1) Bio-Rad Cat# OBT0030CX
Mouse monoclonal anti-RRM2 Clone 1E1 Bio-Rad Cat# MCA3434Z
Rabbit polyclonal anti-KAP-1 Bethyl / Universal Biologicals Cat# A300-274
Rabbit polyclonal anti-Phospho KAP-1 (S824) Bethyl / Universal Biologicals Cat# A300-767
Rabbit polyclonal anti-Phospho KAP-1 (S473) BioLegend Cat# 644602 RRID:AB_2241094
Rabbit polyclonal anti-53BP1 Novus Biologicals Cat# NB100-904
Rabbit polyclonal anti-Phospho-p53 (Ser15) Cell Signaling Cat# 9284
Rat monoclonal anti-RPA32/RPA2 (4E4) Cell Signaling Cat# 2208
Rabbit polyclonal anti-Phospho-Chk1 (Ser296) Cell Signaling Cat# 2349
Rabbit polyclonal anti-Phospho-Chk1 (Ser317) Cell Signaling Cat# 2344
Rabbit polyclonal anti-Phospho-Chk1 (Ser345) Cell Signaling Cat# 2341
Rabbit polyclonal anti-PARP Cell Signaling Cat# 9542
Rabbit polyclonal anti-Cleaved Caspase-3 (Asp175) Cell Signaling Cat# 9661
Anti-mouse IgG, HRP-linked Cell Signaling Cat# 7076
Anti-rabbit IgG, HRP-linked Cell Signaling Cat# 7074
Rabbit polyclonal anti-beta Tubulin antibody Abcam Cat# ab6046
Mouse monoclonal anti-pimonidazole Clone 4.3.11.3) Chemicon International Cat# HP1-100
Alexa Fluor 680 goat anti-mouse IgG (H+L) Invitrogen Cat# A21057
Alexa Fluor 680 goat anti-rabbit IgG (H+L) Invitrogen Cat# A21076
Alexa Fluor 680 donkey anti-goat IgG (H+L) Invitrogen Cat# A21084
IRDye 800CW donkey anti-rabbit IgG Li-Cor Cat# 926-32213
IRDye 800CW donkey anti-mouse IgG Li-Cor Cat# 926-32212
Alexa Fluor 488-conjugated goat anti-rabbit IgG Invitrogen Cat# A11070
Alexa Fluor 488-conjugated donkey anti-rabbit IgG Invitrogen Cat# A21206
Alexa Fluor 488-conjugated goat anti-mouse IgG Invitrogen Cat# A11017
Alexa Fluor 488-conjugated donkey anti-goat IgG Invitrogen Cat# A11055
Alexa Fluor 594-conjugated goat anti-rabbit IgG Invitrogen Cat# A11072
Alexa Fluor 594-conjugated goat anti-rat IgG Invitrogen Cat# A11007
Alexa Fluor 594-conjugated goat anti-mouse IgG Invitrogen Cat# A11020
Alexa Fluor 594-conjugated donkey anti-goat IgG Invitrogen Cat# A11058
Alexa Fluor 555-conjugated goat anti-rat IgG Invitrogen Cat# A21434
Alexa Fluor 488-conjugated goat anti-mouse
F(ab’)2 fragment
Invitrogen Cat# A11017
Pierce Recombinant Protein A/G Thermo Fisher Scientific Cat# 21186
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Bacterial and Virus Strains
BL21-Gold(DE3) Competent Cells Agilent Technologies Cat# 230132
One Shot TOP10 Chemically Competent E. coli Thermo Fisher Scientific Cat# C404010
Chemicals, Peptides, and Recombinant Proteins
Hydroxyurea (HU) Sigma Cat# H8627
Doxorubicin hydrochloride (Adriamycin) Sigma Cat# D1515
5-Bromo-20-deoxyuridine (BrdU) Sigma Cat# B5002
Propidium iodide (PI) Sigma Cat# S7109
Protease Inhibitor Cocktail Roche Cat# 04693159001
CldU (5-chloro-20-deoxyuridine) Sigma Cat# C6891
IdU (5-iodo-20-deoxyuridine) Sigma Cat# I7125
Cytidine 50-diphosphocholine sodium salt dehydrate (CDP) Sigma Cat# C9755
Protein G Sepharose, Fast Flow Sigma Cat# P3296
Isopropyl b-D-1-thiogalactopyranoside (IPTG) Sigma Cat# I6758
Deoxyadenosine 50-Triphosphate, [8-3H(N)] (dATP-H3) Perkin Elmer Cat# NET268250UC
Deoxythymidine 50-Triphosphate ((dTTP) Tetrasodium
Salt) (dTTP-H3)
Perkin Elmer Cat# NET520A250UC
TRIzol Reagent Thermo Fisher Scientific Cat# 15596018
DharmaFECT 1 Dharmacon Cat# T-2001
Lipofectamine Ltx Thermo Fisher Scientific Cat# 15338100
ProLong Gold Thermo Fisher Scientific Cat# P36931
Critical Commercial Assays
Hypoxyprobe-1 Kit for the Detection of Tissue Hypoxia Chemicon International Cat# HP1-100
Real-Time and Dynamic Monitoring of Cell Proliferation
and Viability for Adherent Cells
ACEA Biosciences Inc/
Cambridge Biosc
Cat# 00380601050
SYBR Green PCR Master Mix Applied Biosystems Cat# 4309155
Verso cDNA Synthesis Kit Thermo Fisher Scientific Cat# AB1453B
HisTrap HP columns GE Healthcare Cat# 17-5248-02
QIAprep Spin Miniprep Kit QIAGEN Cat# 27106
QuickChange II XL Site-Directed Mutagenesis Kit Agilent Technologies Cat# 200521
QIAquick PCR Purification Kit QIAGEN Cat# 28106
QIAquick Gel Extraction Kit QIAGEN Cat# 28704
Deposited Data
Original imaging data this study http://dx.doi.org/10.17632/
bp95v48kgm.1
Experimental Models: Cell Lines
RKO ATCC CRL-2577
HCT116 ATCC CCL-247
H1299 ATCC CRL-5803
U2OS ATCC HTB-96
U87-MG ATCC HTB-14
OE21 ECACC 96062201
RKOHIF-1a+/+ and RKOHIF-1a/ Dang L.H. Laboratory Dang et al., 2006
HCT116p53+/+ and HCT116p53/ Vogelstein B. Laboratory Bunz et al., 1998
RKORRM2B/ This paper N/A
Experimental Models: Organisms/Strains
MICE: Female BALB/c nude were used for
xenograft experiments
Charles River, UK
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Oligonucleotides
siRNA-RRM2B (sequence:
UGAGUUUGUAGCUGACAGAUU)
Sigma Piao et al., 2009
siRNA#2 - RRM2B (sequence:
GGAACAAGCUUAAAGCAGA)
Ambion / Life Technologies s224156
siRNA-p53 (sequence:
GUAAUCUACUGGGACGGAA)
Ambion / Life Technologies Leszczynska et al., 2015
AllStars Negative Control siRNA QIAGEN SI03650318
Primers for RRM2B Forward-ChIP (sequence:
CTTGCTGGGAAATCTTGACC)
Sigma Tanaka et al., 2007
Primers used for site-directed mutagenesis Table S1 N/A N/A
Primers used for dNTP incorporation assay Table S1 N/A N/A
Primers used for quantitative PCR (qPCR) Table S1 N/A N/A
Recombinant DNA
Plasmids used in this work are listed in Table S2 N/A N/A
Software and Algorithms
7500 FAST Real-Time PCR thermocycler was used
with v2.0.5 software
Applied Biosystems http://www6.appliedbiosystems.com/
support/software/7500/
The software CAVER 3.0 was used for the analysis
of the evolution of lateral fenestrations during
the MD simulations
N/A N/A
The particle mesh Ewald (PME) algorithm was used
for evaluation of electrostatics interactions
Darden et al., 1993 N/A
The multi time step algorithm Verlet-I/r-RESPA
was used to integrate the equations of motion
Tuckerman et al., 1992;
Verlet, 1967
N/A
The POPS (Parameter OPtimsed Surfaces) algorithm
was used for calculation of the Solvent-Accessible
Surface Area (SASA) of both proteins RRM2B and RRM2
Cavallo et al., 2003; Fraternali
and Van Gunsteren, 1996
N/A
The SETTLE algorithm was used for constrained
the lengths of covalent bonds involving hydrogen atoms
Miyamoto and Kollman, 1992 N/A
Other
For the analysis of RRM2B expression and genetic
alterations in colorectal cancer datasets the
cBioPortal and Prognoscan
http://www.cbioportal.org/;
http://www.abren.net/
PrognoScan/
Gao et al., 2013; Cerami et al., 2012;
Mizuno et al., 2009
Gene Expression Omnibus; Smith et al., 2010 https://www.ncbi.nlm.nih.
gov/geo
accession number GSE17536
ICP-MS was performed with ICP-MS Trace Element
Analysis
https://www.earth.ox.ac.uk/
research/services/geochemical-
analysis/icpms/
N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by, the lead contact, Dr. Ester M. Hammond
(ester.hammond@oncology.ox.ac.uk).
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METHOD DETAILS
Cell culture and treatments
Source of cell lines used in the study is reported in the reagent and resource table. Cells were grown in DMEM with 10% FBS, in a
standard humidified incubator at 37C and 5% CO2. All cell lines were routinely mycoplasma tested and found to be negative.
RKORRM2B/ was constructed in this work using CRISPR-Cas9 technology as previously described (Ran et al., 2013). RRM2B
gene has three isoforms and in order to construct a full knock-out cell line two 20-bp target sgRNA sequences were used target-
ing exon 1: TTCGGCGGAGTCTGCGCGAT (isoforms 1 and 3) and AAATGTTATTCGCCGCGGTC (isoform 2). Lipofectamine Ltx
(Invitrogen) was used for plasmid transfections according to manufacturer’s recommendations (the plasmids used are listed in Table
S2). Dharma-FECT 1 reagent (Thermo Fisher Scientific) was used for siRNA knockdown according to manufacturer’s instructions.
RKO or U2OS cells were transfected with the siRNA sequences reported in the reagent and resource table in a final concentration
of 50 nM.Drugswere purchased fromSigma unless otherwise stated. Hydroxyurea (HU) was used at a concentration of 2mM for 6 hr.
Adriamycin was used at a concentration of 2 mM for 6 hr. BrdU (5-Bromo-20-deoxyuridine) was used at a concentration of 20 mM.
Hypoxia treatment
Hypoxia treatments were carried out in a Bactron II anaerobic chamber (Shell labs) or an In vivo2 400 (Baker Ruskinn) (for oxygen
concentrations at 2%). For experiments at < 0.1% O2 cells were plated on glass dishes. Cells were harvested inside the chamber
with equilibrated solutions. Oxygen concentrations were periodically verified using an Oxylite probe (Oxford Optronix, UK).
Immunobloting and Immonufluorescence
For immunoblots, cells were lysed in UTB (9 M urea, 75 mM Tris-HCl pH 7.5 and 0.15 M b-mercaptoethanol) and sonicated briefly.
The Odyssey infrared imaging technology was used (LI-COR Biosciences) and the Odyssey analysis system was used for quantifi-
cation of the immunoblots. In each case, experiments were carried out in triplicate and a representative blot is shown unless other-
wise stated. The antibodies used in this study are listed in the reagent and resource table.
For immunofluorescence, cells were seeded on autoclaved cover glasses (Menzel-Glaser). At the end of each experiment cells
were fixed with 4% fixation buffer (4% (w/v) paraformaldehyde in PBS), lysed with 1% PBS-Triton X-100 and then incubated with
blocking buffer (2% (w/v) BSA in 0.1% PBS-Triton X-100). Incubation with the appropriate primary and then secondary antibody fol-
lowed (diluted in 2% (w/v) BSA - 0.1% PBS-Triton X-100) (antibodies used are listed in the reagent and resource table). Cells were
visualized using a LSM780 (Carl Zeiss Microscopy Ltd) confocal microscope. At least 100 cells were counted per condition. Due to
the presence of 53BP1 foci in the nuclei of unstressed cells, induction of DNA damage was quantified by counting cells with more
than six foci. Induction of ssDNA was quantified by counting cells with more than six RPA32 foci.
RT-qPCR
RNA was prepared using Trizol (Invitrogen/Life Technologies). For qPCR expression analysis cDNA was reverse transcribed from
total RNA using Verso kit (Thermo Scientific). qPCR was performed using SYBR Green PCR Master Mix kit (Applied Biosystems)
in a 7500 FAST Real-Time PCR thermocycler with v2.0.5 software (Applied Biosystems). mRNA fold change was calculated using
a 2-DDCt method in relation to the 18S reference gene. The qPCR graphs show the mean of three biological replicates ± s.e.m.
The primers used for qPCR are listed in Table S1.
Flow cytometry (FACS)
FACS analysis was performed as previously described (Olcina et al., 2013). U2OS cells were treated with either RRM2B siRNA or
negative control siRNA and were placed in normoxia or < 0.1% O2 (3 hr). Samples were pulsed with BrdU (20 mM) for 30 min before
collection. FACS analysis was carried out using a Becton Dickinson FACSort. Samples were later analyzed using CellQuest Pro and
ModFit LT software. siRNAs and antibodies used are listed in the reagent and resource table.
DNA Fiber analysis and dNTP pool determination
Fiber analysis was carried out as previously described (Foskolou et al., 2016). In brief, sub confluent cells (50%–60% confluency)
were sequentially pulse labeled with 25 mM CldU and 250 mM IdU for 20 min each and left at 21% O2 in a 37
C incubator (normoxic
samples). Cells were washed once with fresh warmmedia before the addition of the second (IdU) label. For hypoxic treated samples,
cells were first placed for 2 hr in the hypoxic chamber (< 0.1%O2) and then treated with 25mMCldU for the indicated times, followed
by the addition of 250 mM IdU for as long as needed for all samples to be in hypoxia for 6 hr in total. At the end of the treatment,
labeled cells were lysed and spread with spreading buffer (200 mM Tris-HCl, pH 7.4, 50 mM EDTA, 0.5% SDS) in a tilting the slide.
DNA fibers were then fixed with methanol/acetic acid (3:1 ratio) and stained with rat anti-BrdU monoclonal antibody (for detection of
CldU labeled tracts) andmouse anti-BrdUmonoclonal antibody (for detection of IdU labeled tracts). Source of antibodies is reported
in the reagent and resource table. Fibers were imaged using a Bio-Rad Radiance or LSM780 (Carl Zeiss Microscopy Ltd) confocal
microscope and analyzed using ImageJ software (NIH). The length of the fiber tracts that had incorporated both labels (CldU and IdU)
wasmeasured and replication rates were calculated with the following formula (VCldU (kb/min) = [(x * 0.132 mm) * 2.59 kb / mm] / t (min),
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dNTP pool determination in whole-cell extracts was carried out as previously described (D’Angiolella et al., 2012). In brief, cells
were seeded in glass dishes and treated either in < 0.1% O2 (for the indicated times) or with 2 mM HU (6 hr). The normoxic samples
were processed immediately after the beginning of the hypoxic and/or HU treatment. Cells were collected and resuspended in 60%
iced cold methanol. Samples were then boiled, centrifuged and the supernatant was dried by centrifugal evaporation and finally dis-
solved in H2O. For the preparation of each primer mix a different set of primers was used (listed in Table S1) supplemented with either
[3H]dATP or [3H]dTTP (PerkinElmer). For dGTP and dCTP determination 1 U of Thermo Sequenase DNA Polymerase (GEHealthcare)
was used; for dTTP determination 1.25 U Klenow Fragment (Thermo Fisher Scientific) and for dATP determination 0.625 U Klenow
Fragment (Thermo Fisher Scientific) was used. The reactions were started by addition of the enzyme. Reactions were incubated for
1 hr either at 48C (for dGTP and dCTP mixtures) or at room temperature (for dTTP and dATP mixtures). Following incubation, the
reaction mixture were spotted onto Whatman DE81 paper (GE Healthcare) and let dry. The papers were then washed with 5%
Na2HPO4, followed by rinsing with distilled H2O and 100% EtOH. After being dried, the radioactivity on the papers was measured
in a LS 6500Multi-Purpose Scintillation Counter (Beckman CoulterTM) using 3.5 mLOptiphase HiSafe 3 (PerkinElmer) counting fluid.
Data present percentage of dNTP incorporation compared to the positive control of each experiment. In experiments where both
siRNA and hypoxia treatment were used, a normalization to each normoxic control was preceded the final analysis.
Immunoprecipitation (IP) and Chromatin IP (ChIP)
IP was carried out as previously described (Zhou et al., 2003). Briefly, RKO cells were lysed in lysis buffer (100 mM NaCl, 20 mM
Tris-HCl pH 7.4, 5 mM MgCl2, 0.5% NP-40) with freshly added phosphatase/protease cocktail inhibitors (Roche). The lysates
were incubated with Protein G Sepharose beads (Sigma) and the antibody of interest RRM1 (Santa Cruz Biotechnology:
sc-11733) or a control IgG antibody (Invitrogen: A10535) with agitation, at 4C overnight. Lysates were washed with lysis buffer
and solubilized in SDS-PAGE sample buffer. Antibodies used were: RRM1 (Santa Cruz Biotechnology: sc-11733), RRM2B (Santa
Cruz Biotechnology: sc-10840), RRM2 (AbD Serotec, MCA3434Z) and for the detection of RRM2 the Pierce Recombinant Protein
A/G (Thermo Fisher Scientific, 21186) secondary antibody was used.
ChIP in RKO cells treated as indicated in figure legend was carried out as previously described (Leszczynska et al., 2015). For each
sample 2 mg of combined mouse p53 (DO-1; sc-126) and rabbit p53 (FL-393; sc-6243) (Santa Cruz) antibodies were used for immu-
noprecipitation. Combined non-specific mouse (7076) and rabbit (7074) (Cell Signaling) were used as control IgGs. A no antibody
control sample was also included in each experiment. Bound fraction and input were analyzed by qPCR using specific primer set
for the RRM2B locus: CTTGCTGGGAAATCTTGACC (Tanaka et al., 2007). Fold enrichment is expressed as a % of input and is
normalized to total p53 in each sample. Graphs show the mean of technical triplicates ± RQmax and RQmin; n = 3.
Colony survival and apoptosis
RKO cells were treated either with RRM2B siRNA or negative control siRNA and exposed to normoxia or hypoxia (< 0.1% O2 for
24 hr). Subsequently all cells were placed in normoxic incubator and left for 9 days to form colonies, which were visualized by crystal
violet staining. Graphs show the mean of three biological replicates ± s.e.m.
Apoptosis assay were performed as previously described (Leszczynska et al., 2015). In brief, both adherent and floating cells were
collected and fixed with 4% paraformaldehyde. Samples were then washed and the nuclei were stained with ProLong Gold
mounting medium with DAPI (Thermo Fisher Scientific). Apoptosis was plotted as the percentage of cells with fragmented DNA
per field of view, with at least ten fields of view quantified per experiment. Each apoptosis experiment was performed at least 3 times.
xCELLigence proliferation assay
The xCELLigence Real-Time Cell Analyzer (ACEA Biosciences) DP Instrument equipped with an E-Plate was used for proliferation
assays. Cells were seeded into 100 mL of media in 96X microplates. The attachment, spreading and proliferation of the cells were
monitored every 15 min for 60 hr. For quantification, the cell index at indicated time points was averaged from three independent
experiments. Values are presented as mean ± SEM of three independent experiments.
Xenografts and tissue IF staining
All animal procedures were performed in accordance with current UK legislation and were approved by the University of Oxford
Biomedical Services Ethical Review Committee, Oxford, UK. For the tumor growth curves (xenografts), female BALB/c nude mice
or female athymic nude mice (Charles River, UK) were randomized and injected subcutaneously with 3 3 106 RKORRM2B+/+ or
RKORRM2B/ cells in 25% (v/v) matrigel and serum-free DMEM. Tumor growth was monitored until they reached approximately
300-400mm3 (volume = height x depth xwidth xp / 6). For the irradiation experiment, the tumors in half of the animals were irradiated
with 10 Gy when tumor volumes reached 100 mm3. Tumors were measured regularly, and tumor growth was plotted as a mean of
tumor volumes ± SEM.Mice were injected with 50mg/kg of pimonidazole (PIMO) 2 hr before the end of the experiment. Tumors were
split in half and either preserved in formalin for wax embedding or were snap frozen and embedded in optimal cutting temperature
compound (OCT).
Tissue IF staining were performed as previously described (Leszczynska et al., 2015). In brief, tumors embedded in OCT were
sectioned (5 mm) and froze down at 20C. Sections were immediately fixed with 4% paraformaldehyde and then quenched with
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Reagent (Vector Laboratories). The sections were stained with PIMO and cleaved caspase-3 primary antibodies, followed by
secondary antibodies (listed in the reagent and resource table) and mounted with ProLong Gold mounting medium with DAPI
(Invitrogen/Life technologies). The apoptotic cells were counted within and outside of hypoxic regions. Images were taken from at
least 3 RKORRM2B+/+ and 3 RKORRM2B/ tumors. Graphs show the percentage of apoptotic cells from all normoxic or hypoxic
regions.
TCGA RNA-sequencing (RNA-seq) analysis and analysis of colorectal cancer datasets
Raw RNA-seq data for 382 colorectal adenocarcinoma tumors were downloaded from the TCGA project (accessed through
cBioportal: http://www.cbioportal.org/). To examine tumor-associated HIF-activity (referred to as hypoxia signature), raw data
for each sequenced gene were rescaled to set the median equal to 1, and HIF-activity was quantified by averaging the normal-
ized expression of 44 target genes, associated with HIF activity (encoding ADM, GFBP3, EDN2, PFKFB4, FLT1, TFR2, BNIP3L,
TGFA, BNIP3, PGK1, EGLN1, LDHA, EGLN3, CP, TGFB3, PFKFB3, HK1, TFRC, EDN1, CDKN1A, CA9, HMOX1, SERPINE1, LOX,
NDRG1, CA12, PDK1, VEGFA, ERO1L, RORA, P4HA1, MXI1, SLC2A1(GLUT1), STC2, MIF, DDIT4, ENO1, CXCR4, PLOD1,
P4HA2, GAPDH, PGAM1, TMEM45A and PIM1) (Li et al., 2014). Log10 conversion of the hypoxia signature was plotted against
Log10 conversion of raw data for RRM1, RRM2 and RRM2B. Two-tailed p value shown on each graph for each Pearson and
Spearman r (correlation coefficient).
To examine tumor-associated p53-activity (referred to as p53 group), raw data for each sequenced gene were rescaled to set the
median equal to 1, and p53-activity was quantified by averaging the normalized expression of 6 p53 target genes, associated with
hypoxia-induced p53 activity (encoding BTG2, CYFIP2, INPP5D, KANK3, PHLDA3 and SULF2) (Leszczynska et al., 2015, 2016).
Log10 conversion of the p53 signature was plotted against Log10 conversion of raw data for RRM2B (also rescaled to set themedian
equal to 1). Two-tailed p value shown on each graph for each Pearson and Spearman r (correlation coefficient).
For the analysis of RRM2B expression and genetic alterations in colorectal cancer datasets the cBioPortal (http://www.cbioportal.
org/) and Prognoscan (http://www.abren.net/PrognoScan/) tools were used on the 5th Dec 2016 (Gao et al., 2013; Cerami et al.,
2012; Mizuno et al., 2009). Using cBioPortal the TCGA (provisional) dataset was analyzed (RNA Seq V2 RSEM) for alterations,
including mutations, putative copy-number alterations, mRNA expression, mutations and survival probability (629 cancer patients).
For the Prognoscan analysis, RRM2B expression was checked in all available colorectal cancer datasets and Kaplan-Meier graphs
were extracted only for the statistically significant (p < 0.05) dependence between RRM2B expression (probe 223342_at) and survival
probability. This analysis used the publicly available dataset at Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo) with
the accession number GSE17536 (Smith et al., 2010).
Protein overexpression and purification
The 6 3 His-tagged hRRM1 (pET28a-RRM1) was kindly provided by Prof JoAnne Stubbe (Massachusetts Institute of Technology,
Cambridge, USA), expressed in E.coli BL21-Gold (DE3) competent cells (Agilent Technologies) and as previously described
(Ando et al., 2016). The 6 3 His-tagged hRRM2 and hRRM2B (pET28a-RRM2, pET28a-RRM2B) were kindly provided by Dr. Yun
Yen (Beckman Research Institute at City of Hope, Duarte, USA). The proteins were expressed in E.coli BL21-Gold (DE3) competent
cells (Agilent Technologies) and purified as previously described (Shao et al., 2004) with minor modifications. Specifically, an over-
night culture of the transformed bacteria was diluted 80-fold in 600 mL of 2 3 YT medium containing 50 mg/ml kanamycin. Each
culture was grown at 37C until OD600nm = 0.7 - 0.9 and then induced by 1 mM isopropyl-1-thio-b-D-galactopyranoside (IPTG)
and incubated overnight at 18C. Cells were harvested by centrifugation and the pellets were lysed with appropriate amount
(5 ml/gr of pellet) Lysis Buffer (50 mM NaH2PO4 pH 7.0; 0.1% Triton X-100; 10 mM b-mercaptoethanol; freshly added EDTA-free
Protease Inhibitors and DNase I) at 4C with vigorous agitation until the lysate was homogeneous. The lysate was then sonicated
(60%Amplitude 30 sON / 30 sOFF) and clarified by centrifugation at 48,0003 g for 20min at 4C. Soluble lysate was passed through
a His-Trap HP purification column (GEHealthcare), washedwith at least 30-fold bed volume ofWash Buffer (50mMNaH2PO4 pH 7.0;
800 mM NaCl; 50 mM imidazole; 0.1% Triton X-100; 10 mM b-mercaptoethanol) and finally eluted with Elution Buffer (50 mM
NaH2PO4 pH 7.0; 300mMNaCl; 125mM imidazole). The protein then underwent buffer exchange into 25mMTris-HCl, pH 7.5 before
being concentrated and stored at 80C. The purified proteins showed approximately 90% purity. The apo-forms of RRM2 and
RRM2B recombinant proteins used in ICP-MS experiments were overexpressed and purified as previously described (Wang
et al., 2009a). Site-specific mutations in RRM2B (Y164C; Y164F; F183Y; K31E/K151E; Y241H; Y331F and Q127K) were generated
by PCR, using the pET28a-RRM2B as a template and theQuickChange II XL Site-DirectedMutagenesis Kit (Agilent Technologies). All
constructs were verified by DNA sequencing. Expression and purification of the hRRM2B mutated proteins were performed in the
same way as for hRRM2B.
dCDP formation assays
The activity of recombinant RNRwasmeasured using the following reduction method. The enzyme concentration (R1/R2B or R1/R2)
was the same in all cases and the limited factor was the presence or not of oxygen (normoxia versus hypoxia). Specifically, a final
concentration of 1.25 mM of purified RRM1 was incubated with 2.5 mM of either RRM2 or RRM2B protein. The reaction mixture con-
tained 0.1 mMCDP, 50 mMHEPES (pH 7.5), 6 mMDTT, 8 mMmagnesium acetate, 2 mM ATP and 1 mMNADPH in a final volume of
400 ml. The RNR proteins purified were active without reassembling the iron center (Shao et al., 2004; Zhou et al., 2010). In hypoxice6 Molecular Cell 66, 206–220.e1–e9, April 20, 2017
samples (< 0.1%O2) the reaction mixture was assembled and the assay was carried out within an anaerobic chamber (Bactron, Shel
Labs). Reactions were initiated by the addition of CDP, incubated at 37C and aliquots of 50 ml were quenched by the addition of 10 ml
of 3% tricarboxylic acid over a time course of the reaction. Subsequent dCDP and CDP levels were analyzed by HPLC. Graphs
present either percentage of dCDP formation when normoxia and hypoxia were compared (data were normalized against the nor-
moxic samples at 37C at 30min where the dCDP formation was considered 100%) or in mMwhen the accumulation of dCDP formed
in < 0.1% O2 at a 0-120 min time course was examined.
Determination of CDP/dCDP
CDP and dCDP levels following RNR activity assays were determined by ion-pairing HPLC with UV detection (270 nm). HPLC was
performed using a Shimadzu system with a photodiode array detector. The column was an ACE C 18, 3 mm, 1253 3 mm (Hichrom)
maintained at 35C. A gradient separation was achieved using 10%methanol, 10 mM KH2PO4, 10 mM TBAOH, pH 6.9 (A) and 30%
methanol, 50 mM KH2PO4, 6 mM TBAOH, pH 7.0 (B), with a linear gradient of 25 – 47% B over 8 min, 47 – 80% B over 1 min, then
returning to the started conditions 3 min. The flow rate was 0.6 ml/min and the running time was 16.5 min.
Circular dichroism spectrometry
Circular dichroism (CD) spectra (Chirascan CD/Fluorimeter spectrometer (Applied Photophysics, UK) of hRRM2B and the mutants
(0.2 mg/mL) were recorded in the wavelength range 260 to 185 nm in 100 mmol/L potassium phosphate buffer (pH 7.5). All measure-
ments were carried out at 37C using a 0.1-cm path length quartz curette. The data pitch was 0.1 nmwith a 1-nmbandwidth at a scan
speed of 1.0 nm/s. Each spectrum shown represents the average of three. All CD data were expressed as themean residue ellipticity,
[q], deg$cm2$dmol-1.
Inductively coupled plasma mass spectrometry (ICP-MS)
The Thermo Finnigan Element 2 ICP-MS was used for quantitation of iron content in the recombinant purified proteins (40 mg of pro-
tein was used per 50 ml of reaction). Calibrations were obtained using external standards (a series of standards of known Fe concen-
trations were prepared and analyzed to gain a calibration linear, prior to the measurement of the samples). An external standard was
diluted and measured from a dilution of High Purity Standards 10 ppm ICP-MS-68 A standard. All blanks, standards and samples
were also spiked with 1 ng/g Rh, so that any general instrument drift could be normalized. Dilutions were made using a 2% HNO3
solution, prepared using in-house distilled nitric acid and 18.2 Mohm DI water. All data results were first reported as elemental con-
centrations and then calculated in nM of Fe per mM of protein. Additional information can be found at (https://www.earth.ox.ac.uk/
research/services/geochemical-analysis/icpms/).
Electron paramagnetic resonance (EPR)
CW-EPR spectra were collected in the Center for Advanced ESR (CAESR) in the Inorganic Chemistry Laboratory at the University of
Oxford. X-band measurements utilized a Bruker-Biospin Micro EMXplus spectrometer equipped with a PremiumXmicrowave bridge,
a cylindrical TE011-mode resonator (SHQE-W), an ESR-900 liquid helium cryostat, and an Oxford Instruments ITC-503 s temperature
controller. Measurements were performed within the limit of resolution by temperature, 40K, and under non-saturating conditions.
The protein concentration for all EPR samples was 200 mM except for RRM2 protein, which was 70 mM. The protein samples
(RRM2B, RRM2 or RRM2B mutants) were diluted in 50 mM HEPES, pH 7.5 and were incubated either at 37C for 5 min with oxygen
present (normoxia) or at 37C for 60 min in a Bactron II anaerobic chamber (< 0.1% O2). At the end of each treatment 20% (v/v) glyc-
erol was added for vitrification during the low-temperature recordings. Samples were then transferred to EPR tubes and quick-frozen
by immersion in liquid nitrogen. Spin quantitation was performed using the Bruker spectrometer hardware spin calibration, given the
input dimensions of the precision Wilmad PQ-706 tubes. The results were verified with a 1 mM CuII EDTA in 50 mM HEPES pH 7.5,
20% (v/v) glycerol that was measured under non-saturating conditions at 100 K with 50 mWmicrowave power. The results show spin
equivalents per b-subunit.
Molecular Dynamics (MD) simulations
System setup:MD simulations of O2 transport on hRRM2B (PDB: 3HF1; resolution 2.60 A˚) and hRRM2 (PDB: 3VPN; resolution 2.25 A˚)
were performed (Smith et al., 2009). The RRM2B structure comprises residues S29 to F311. The 3VPN X-ray structure is that of
the E106D variant of native RRM2, and comprises residues M65 to M350. Four simulations were performed in which 200 randomly
chosenwatermolecules outside the solvated protein were replaced by 200O2molecules (0.5M) termed the 100%oxygen level simu-
lation. The randomdistribution of oxygenmolecules precludes any potential artifacts arising from initial distribution. An additional two
sets of simulationswereperformed to control for concentration effects; the first set uphas a tenfold reduction in oxygenconcentration,
termed 10% oxygen level simulation with effective concentration of 50 mM, for RRM2B and RRM2. The second set does not include
any oxygen molecules, termed 0% oxygen level simulation. Each system was solvated in a box of dimensions (80, 80, 92) A˚ using
the Solvate plug-in of VMD (Humphrey et al., 1996), with the total system size comprising 61,000 atoms. In accordance with the
Uniprot sequence alignment two mutants of native RRM2B were prepared with the Mutate plugin in VMD (Humphrey et al., 1996),
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MD equilibration protocol
Calculations were done with NAMD 2.9 (Phillips et al., 2005), using the CHARMM 27 protein force-field (Brooks et al., 2009) with the
CMAP correction (Buck et al., 2006), together with the TIP3P water model (Jorgensen et al., 1983). Oxygen Lennard-Jones param-
eters were taken from CHARMM (Cohen et al., 2005, 2006). For O2 gas access in RRM2B and RRM2, the iron centers were modeled
using CHARMM 27 force-field, with iron Lennard-Jones parameters εO = 0.00 kcal/mol and Rmin/2 = 0.65 A˚. Oxygen (O2) was
modeled using CHARMM 27 Lennard-Jones parameters from heme oxygen, εO = 0.12 kcal/mol and Rmin/2 = 1.7 A˚, as well as
bond spring constants and bond spring lengths for O2 as 1.23 A˚ and 600 kcal/mol/A˚
-1, respectively. RRM2B contains the same
diiron/dityrosyl cofactor that RRM2 does, and both RRM2B and RRM2 are biologically active as homodimers. In RRM2B, the active
site iron coordination environment inMonomer-1 is amono-iron site, andMonomer-2 has a di-iron site. In RRM2B, the active site iron
coordination environment consists in both Monomer-1 and 2 of mono-iron sites.
After 1,000 steps of Conjugate-Gradient minimization, four classical molecular dynamics (MD) simulations of the O2-containing
solvated protein were carried out for 300 ns in the NPT ensemble. The high oxygen concentration was necessary to ensure sufficient
sampling of protein cavities by O2 on the accessible timescale of current simulations. It was verified that no gas clustering occurred in
the solvent at this concentrations. The particle mesh Ewald (PME) algorithm was used for evaluation of electrostatics interactions
beyond 12 A˚, with a PME grid spacing of 1 A˚, and NAMD defaults for spline and k values (Darden et al., 1993). A cut-off at 12 A˚
was applied to non-bonded forces, both electrostatics and Van der Waals forces were smoothly switched off between the cut-off
distance of 12 A˚, and the switching distance of 10 A˚, using the default NAMD switching function. A Verlet neighbor list with pairlist
distance of 14 A˚ was used to only evaluate non-bonded neighboring forces within the pairlist distance (Verlet, 1967). The lengths of
covalent bonds involving hydrogen atoms were constrained by the SETTLE algorithm (Miyamoto and Kollman, 1992) in order to be
able to use a 2-fs time-step. The multi time step algorithm Verlet-I/r-RESPA (Tuckerman et al., 1992; Verlet, 1967) was used to inte-
grate the equations of motion. Non-bonded short-range forces were computed for each time step, while long-range electrostatic
forces were updated every 2 time steps. The pressure was kept at 1 atm by the Nose´-Hoover Langevin piston (Langevin, 1908;
Nose´, 1984a, 1984b), with a damping time constant of 50 fs and a period of 100 fs. The temperature was maintained at 300 K by
coupling the system to a Langevin thermostat, with a damping coefficient of 1 ps-1. A total of 3.0 ms of MD simulations were accrued.
Code availability
The standardMPI version 2.9 of the MD simulation code NAMDwas employed (Phillips et al., 2005). A free license can be obtained at
http://www.ks.uiuc.edu/Research/namd/. Version 1.9 of Visual Molecular Dynamics (VMD) was employed for analysis, with license
obtained at http://www.ks.uiuc.edu/Research/vmd/.
MD simulation analysis
The Solvent-Accessible Surface Area (SASA) of both proteins RRM2B and RRM2 was calculated using the POPS (Parameter
OPtimsed Surfaces) algorithm (Cavallo et al., 2003; Fraternali and Van Gunsteren, 1996). The bending angle of helices was estimated
using Bendix in VMD (Dahl et al., 2012).
The Diffusion-Reaction Model (Wang et al., 2013) presented in Equation (1) was adopted to describe the diffusion of O2 into the
RNR active site:
Enz+Gas%
Kin ½O2 
Kout
EnzGas: (1)
This is a kinetic two-step model consisting of an initial diffusion step of the gas molecule, followed by a metal-gas molecule chem-
ical reaction step (Wang et al., 2011;Wang and Blumberger, 2012). Here, a classical force-field (FF) was employed, and only the diffu-
sion and binding of O2 gas molecules to the RNR iron center were modeled:
RNRðFeÞ+O2%
k+ 1
k1
RNRðFeÞ/O2: (2)
The simulation of O2 diffusing in the solvated RNR enzymes yields diffusion statistics that enable the construction of a probability
density map of the O2-distribution within RNR (RRM2B or RRM2). This distribution is then divided into a set of M discrete protein
cluster states that correspond to the probability maxima. Two parameters are used to characterize the diffusion of O2. First, a dis-
tance criterion is established to determine when an oxygenmolecule has entered into the active site of hRRM2B and hRRM2, defined
as the difference between the center-of-mass (COM) of the iron ion and the O2 molecule. Second, cut-off criteria of 8 A˚, 9 A˚ and 10 A˚
were employed to generate statistics of the O2 entering. An O2 molecule is counted as having entered the cluster if dCOM (O2-Fe) < c
where c is 8 or 9 A˚.
Free-energy simulations of tunnel entry
Oxygen entry tunnels were assigned and characterized from classical MD simulations. As previously described, O2 entry into WT
RRM2B and RRM2 was identified to occur primarily through Tunnels T1, T2 and T3. Based on this assignment, equilibrium
Adaptive-Biasing Force (ABF) MD simulations (Chipot and Pohorille, 2007; Darve and Pohorille, 2001; Darve et al., 2008; Van
Gunsteren, 1989) were performed on oxygen entry into tunnels T1, T2 and T3 in Monomer-1 to determine relative differences ine8 Molecular Cell 66, 206–220.e1–e9, April 20, 2017
the thermodynamics of oxygen entry into RRM2B and RRM2. In total, six ABF simulations per RNRwere performed, totallingz0.5 ms
of MD simulation dynamics. Each ABF simulation was performed with a force bias on a single oxygen molecule meaning these sim-
ulations constitute single-molecule biased MD simulations, using the collective variable x center-of-mass (COM) distance between
Fe(III) and O2, xðrNÞ=dðO2  FeðIIIÞÞ, with x ranging from 3 A˚ to 15A˚, in bins of width 0.25 A˚. Each ABF simulation obtains ergodic
sampling by applying every 500 timesteps a biasing force FABF (3) onto the Newtonian equations of motion, whose value is updated
on-the-fly (Den Otter, 2000; Den Otter and Briels, 1998) From the result, free-energy gradient along x, the Potential of Mean Force
(PMF) along x is obtained from numerical integration of the gradient.
FABF =Vr~A =  hFðxÞixVrx (3)
dGðxÞ
dx

=

vUðrNÞ
vx

 b1

vIn
J
vx

=  hFðxÞix: (4)
Tunnel T1 in Monomer-1 extends for30 A˚ and connects the two faces of the protein. It was simulated as two separate tunnels of
length 15 A˚ in Monomer 1, denoted Tunnel T1 and T1’, and was compared to a single simulation of Tunnel T1 in Monomer 2. Two
simulations of Tunnels T2 and T3 were performed in RRM2B and RRM2.
Analysis of fenestrations
The software CAVER 3.0was used for the analysis of the evolution of lateral fenestrations during theMD simulations, using 100 evenly
chosen snapshots from theMD simulations, which is every 2 ns. The outer surface of the protein is calculated by rolling a large spher-
ical probe around the surface of the protein and then internal cavities are identified using a smaller spherical probe (a radius of 0.8 A˚
was used here, and 12 probe spheres used). All identified tunnels are grouped into clusters based on relative proximities and with an
8 A˚ cut off for each cluster node, meaning that tunnels differing from the node by more than 8 A˚ are excluded. The values for shell
radius and depth (15 A˚) influence the definition of the protein molecular surface.
Statistical analysis
The statistical significance of differences between datasets was determined assessed by using the following test. Student’s t test
(two-tailed paired, except for dNTP incorporation assays, where a two-tailed unpaired test was applied) was used in all experiments
where twomeanswere compared. One-way analysis of variance (ANOVA) was used to compare several means and two-way ANOVA
was used for determination in a response that is affected by two factors (one- or two-way ANOVA analysis is indicated at the figure
legends). Statistical significance was assumed if p < 0.05 or lower and is noted in the figures. Error bars represent mean ± standard
error of the mean (s.e.m.).
DATA AND SOFTWARE AVAILABILITY
Original imaging data have been deposited to Mendeley Data and are available at http://dx.doi.org/10.17632/bp95v48kgm.1Molecular Cell 66, 206–220.e1–e9, April 20, 2017 e9
